- Home
- PPLI vs RCUS Comparison
PPLI vs RCUS Comparison
Compare PPLI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPLI | RCUS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 5156 | 601 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PPLI | RCUS |
|---|---|---|
| Price | $41.69 | $28.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $31.90 |
| AVG Volume (30 Days) | 821.9K | ★ 1.3M |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.05 | $8.84 |
| 52 Week High | $48.32 | $31.74 |
Technical Indicators
Market Signals| Indicator | PPLI | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 51.38 |
| Support Level | $41.78 | $20.20 |
| Resistance Level | $48.21 | $28.72 |
| Average True Range (ATR) | 1.20 | 1.33 |
| MACD | -0.63 | -0.16 |
| Stochastic Oscillator | 0.85 | 50.83 |
Price Performance
Historical ComparisonAbout PPLI People Incorporated Common Stock
People Inc is a media and publishing business that operates a portfolio of brands, including PEOPLE, Food & Wine, Travel + Leisure, InStyle, Better Homes & Gardens, and Southern Living. The company also holds a minority equity stake in MGM Resorts International.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.